Quintrio
Home

Stock overview

Smith & Nephew plc

SNN

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.

Last trade $30.56
Day change -$0.41 (-1.32%)
Day range $30.49 – $31.08
Volume 916,003
Market cap $12.95B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for SNN.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for SNN.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets

Smith+Nephew announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant across 12 key markets, expanding its Sports Medicine portfolio. The product is backed by clinical evidence showing superior knee outcomes and pain relief over five years. The global cartilage repair market is projected to grow from $5.98 billion in 2024 to $8.04 billion by 2030 at a 5.1% CAGR.

GlobeNewswire Inc.

Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal

Smith+Nephew announced the commercial availability of its CARTIHEAL AGILI-C cartilage repair implant in Europe, following its 2024 US launch. The aragonite-based implant demonstrated clinical superiority over standard care in a multicenter randomized controlled trial, showing superior pain relief and functional gains over 5 years. The product will initially be available in 12 European countries.

GlobeNewswire Inc.

Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.

Smith+Nephew announced the commercial launch of CARTIHEAL AGILI-C, an innovative cartilage repair implant, across Europe. The aragonite-based scaffold will be presented at the ICRS Summit in Portugal (October 8-10). A randomized controlled trial published in the American Journal of Sports Medicine demonstrated clinical superiority over standard surgical care, with patients showing improved pain relief and functional outcomes over 5 years. The implant will initially be available in 8 European countries with plans for further expansion.

Zacks Investment Research

Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care

Smith+Nephew (SNN) launched the EVOS PELVIC Plating System to expand its orthopedic trauma portfolio into pelvic and acetabular fracture management. The system features dedicated plates, cannulated screws, and specialized instruments designed to improve surgical efficiency. The global pelvic trauma market is projected to grow from $2.81 billion in 2025 to $4.79 billion by 2034 at a 6.1% CAGR, driven by increased high-energy fractures and wider adoption of surgical fixation protocols.

GlobeNewswire Inc.

Explosive Growth in AI for Orthopedic Surgery Market: $0.87 Billion by 2030 at 27.2% CAGR

The AI in orthopedic surgery market is experiencing remarkable growth with a projected CAGR of 27.2% through 2030. Key drivers include rising musculoskeletal disorders, AI-assisted surgical planning, robotic surgical systems integration, and enhanced implant placement precision. North America leads the market, while Asia-Pacific and Europe show growing segments despite tariff-related challenges.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Oct 2, 2026$0.312Nov 6, 2026recurring
Mar 27, 2026$0.482May 27, 2026recurring
Oct 3, 2025$0.30Nov 7, 2025recurring
Mar 28, 2025$0.462May 28, 2025recurring
Oct 4, 2024$0.288Nov 8, 2024recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 15, 20142.5-for-1forward split
Dec 16, 20032-for-1forward split